Jeena Sikho Lifecare (JSLL) Q2 24/25 earnings summary

Executive summary

• H1FY25 revenue from operations was ₹21,412.93 lakh, up 36% YoY; PAT was ₹4,687.91 lakh, up 47%.

• The network reached 36 hospitals and 74 clinics/day-care centres across 21 states and 100+ cities and towns; operational beds rose to 1,530.

• The model combines healthcare services with Ayurveda products, cross-selling and a capital-light mix of owned and franchise facilities.

Financial highlights

• H1FY25 revenue from operations was ₹21,412.93 lakh vs ₹15,736.00 lakh; total income was ₹22,008.46 lakh vs ₹15,884.97 lakh.

• EBITDA was ₹5,928 lakh, up 32% YoY; EBIT was ₹5,624 lakh, up 32%; PAT was ₹4,687.91 lakh vs ₹3,182.69 lakh.

• Total expenses were ₹15,808.27 lakh vs ₹11,515.45 lakh; other income was ₹595.53 lakh vs ₹148.97 lakh.

• Cash and cash equivalents at Sep. 30, 2024 were ₹2,852.48 lakh vs ₹1,235.16 lakh a year earlier.

Outlook and guidance

• Priorities include improving utilization of existing assets, opening new centres and adding beds at existing centres.

• Plans include new product kits, OTC medicine sales through pharmacies in H2FY25 and expanding cashless insurance access.

• Broader coverage under government panels and AYUSH is expected; 20 additional facilities and 518 beds are in the pipeline.

• EBITDA margin pressure from new-hospital operating costs is expected to normalize as revenue from recently opened hospitals builds.